Dr. BALAMURALI VENKATESAN

@drmgrdu.ac.in

ASSISTANT PROFESSOR, DEPARTMENT OF MICROBIOLOGY, FACULTY OF MEDICINE
Assistant Professor, Department of Microbiology, Sri Lalithambigai Medical College and Hospital, Faculty of Medicine, Dr. MGR Educational and Research Institute, Service Rd, Maduravoyal, Adayalampattu, Chennai-600095, Tamil Nadu, India.

Dr. BALAMURALI VENKATESAN


                        Download Compact PDF  
https://researchid.co/balajai96

RESEARCH, TEACHING, or OTHER INTERESTS

Microbiology, Immunology and Microbiology, Virology, General Immunology and Microbiology
11

Scopus Publications

48

Scholar Citations

4

Scholar h-index

1

Scholar i10-index

Scopus Publications

  • Nanoplatform-based theranostics in glioblastoma: A promising frontier for precision oncology
    Kesavarajan Govindarajan Karthikeyan, Balamurali Venkatesan, Natarajan Vaghesan, Pavithra Selvan, Sakthinarenderan Saikumar
    Nano Trends, 2025
    • Targeted nanoparticles provide enhanced medication delivery across the blood-brain barrier. • Theranostics facilitates real-time imaging of glioblastoma therapy. • Stimulus-responsive nanoparticles provide regulated and accurate drug delivery release. Glioblastoma (GBM) is the most aggressive primary brain neoplasm, characterized by a poor prognosis and resistance to standard treatments. The tumor's infiltrative characteristics and the tight blood-brain barrier (BBB) impede effective therapy. Recent advancements in nanoplatform-based theranostics provide a novel approach by combining targeted drug delivery with real-time diagnostic imaging. Multifunctional nanoparticles, including liposomal, dendrimers, polymeric, and inorganic systems, may be designed to traverse the blood-brain barrier, specifically target glioblastoma cells, provide controlled drug release, and offer molecular imaging using MRI, PET, or fluorescence techniques. Surface modification using ligands or antibodies, such as transferrin or EGFR-targeting agents, improves tumor selectivity and reduces systemic toxicity. Furthermore, stimuli-responsive designs provide site-specific medication activation inside the tumor microenvironment, enhancing therapeutic precision. Preclinical investigations have shown substantial improvements in medication bioavailability, imaging precision, and survival outcomes in GBM models. Despite these breakthroughs, translational obstacles endure, including large-scale synthesis, repeatability, and regulatory approval. Mitigating these hurdles by GMP-scale manufacturing, economical formulations, and multidisciplinary cooperation may expedite clinical acceptance. Nanotheranostic technologies signify a potential advancement in precision oncology, providing concurrent diagnosis, tailored treatment, and real-time monitoring—facilitating personalized and successful management of GBM.
  • Clinico-Mycological Analysis of Ocular Infections in Immunocompetent vs. Immunocompromised Patients
    V. Natarajan, Kalyani A. Akhila, Nandini Dhanapal, Pavithra Selvan, Balamurali Venkatesan
    Research Journal of Biotechnology, 2025
    Fungal pathogens have a crucial role in causing eye infections worldwide, which can often result in avoiding blindness. The use of corticosteroids has contributed to the recent surge in occurrences of fungal keratitis. The aim of this study was to determine the occurrence of ocular fungal infections in patients with immunocompetent and immunosuppressed patients. The study divided 184 case into two groups: immunocompetent and immunocompromised. We directly examined collected clinical samples under a microscope using a KOH mount and a modified LPCB mount, before exposing them to fungal culture. These diagnostic techniques made it easier to identify fungal species in the samples. Both groups showed keratitis as the most common clinical symptom. In patients with a normal immune system, trauma was the main factor that made them more susceptible to the condition, whereas in patients with a weakened immune system, systemic candidiasis was the most common contributing factor. Fusarium was the predominant causal agent in immunocompetent patients while immunocompromised individuals more frequently observed Candida and Aspergillus species. These findings emphasise the need to take into account a patient's immunological condition when diagnosing and treating ocular fungal infections. This calls for additional research to improve treatment approaches and to evaluate antifungal susceptibility on a broader level.
  • Microbiological Spectrum of Infectious Keratitis: Insights from a Multi-speciality Hospital Setting
    V. Natarajan, Balamurali Venkatesan, Kalyani A. Akhila, Pavithra Selvan, Veena Hemanth
    Research Journal of Biotechnology, 2025
    Microbial keratitis (MK) is a prevalent eye condition that leads to vision impairment and poses significant risks to ocular health. It occurs when bacteria, fungi, viruses, or parasites infect the cornea, causing damage through their virulence factors or triggering harmful immune responses. The incidence of infectious keratitis is notably higher in developing countries, especially in regions with low education, inadequate sanitation and poor hygiene. This study aimed to identify the microbiological profile of MK and to explore its socio-demographic components. This time-bound, cross-sectional research involved patients who attended Multi-specialty hospital between January 2022 and June 2024 (18 months). A total of 361 patients were recruited for the study. Of the 315 samples that tested positive for microbes (87.2% of the total), 188 (59.6%) had been found to have bacteria. Among Gram-positive organisms, Coagulase-negative staphylococci (CNS), was the most predominant organism isolated, accounting for 86 (45.7%) of the cases. Of Gram-negative bacteria, Pseudomonas aeruginosa was shown to be a prominent culprit, responsible for 32 cases (17.1%) and Escherichia coli was found to be involved in 26 cases (13.8%). Out of the 127 culture positive cases, the majority of fungi were Fusarium species 54 (42.7%), Aspergillus species 46 (36.2%), Candida species 21 (16.5%), Curvularia species 3 (2.3%), Penicillium species 3 (2.2%), F. solani 42 (77.8%), F.semitectum 7 (12.9%) and F. dimerium 5 (9.3%).
  • Rise of Carbapenem-Resistant Escherichia coli and the Concerning Existence of blaNDM-1 Gene in Gut Microbiota of Rural Populations
    Alankritha Yadhunandan, R. Sujith Sri Surya, Leela Kakithakara Vajravelu, Balamurali Venkatesan, P. Deeksha, Dakshina M. Nair
    Journal of Pure and Applied Microbiology, 2024
    In rural communities, the blaNDM-1 gene in the gut microbiota may be contributing to the growing issue of antibiotic resistance. This gene enables bacteria to produce enzymes that break down antibiotics, making treatments less effective. The limited healthcare resources and frequent exposure to resistant bacteria in these areas could further amplify this problem, increasing the risk of difficult-to-treat infections among the population. The objective of this study was to evaluate the antimicrobial susceptibility of Escherichia coli [E. coli] strains isolated from healthy individuals and to assess the prevalence of blaNDM-1 gene carriage. The samples were cultured and identified as gut commensal by conventional method. Then antibiotic susceptibility test using the Kirby Bauer disc diffusion method were carried out. Carbapenem-resistant organisms were isolated, and the blaNDM-1 was identified by polymerase chain reaction. This study includes 187 Healthy participants faecal samples were obtained from people in and around the Chengalpattu area. Out of 187 samples, 110 showed E. coli growth, 63 showed Enterococci species growth, and 14 showed no growth. Among the 110 E. coli isolates, 24 (21.8%) were sensitive to all drug classes, and 86 (78.2%) were multidrug resistant. Only 8(7.27%) of the 110 E. coli tested positive for carbapenem resistance. Out of 110 E. coli isolates, only (2.7%) had the blaNDM-1 gene. This study discovered that rural communities that are unlikely to be subjected to obvious antibiotic pressure had a high incidence of MDR microorganism faecal carriage. Finding resistance genes in commensal bacteria is alarming. This has the ability to spread and emerge in the environment.
  • Association of Robust Anti-SARS-CoV-2 Trajectories among Communities with and without COVID-19 Infection
    Balamurali Venkatesan, Leela Kakithakara Vajravelu, Sujith Ravi, Jayaprakash Thulukanam, Om Lokesh Muthamilan
    Journal of Pure and Applied Microbiology, 2024
    Globally, 767 million people have been affected by SARS-CoV-2 infection and nearly a population of 6.94 million were deceased as per the World Health Organization (WHO) as of June 7, 2023. In India, the spreading of infections is now being restricted by the use of BBV-152 (CovaxinTM) and ChAdOx1-nCOV (CovishieldTM) vaccines. The present study comprises 327 candidates and Chemiluminescent microparticle immunoassay (CMIA) was used as a quantitative analytical tool to detect IgG and IgM antibodies. Out of 327 candidates, 177 (54.1%) were vaccinated and 150 (45.9%) were non-vaccinated. Among vaccinated and non-vaccinated candidates, 49 (27.7%%) and 44 (29.3%) had a history of infection, respectively; meanwhile, most of the study participants were immunized with CovishieldTM (n=145, 81.9%) and 18.1% (n=32) were immunized with CovaxinTM. There were insignificant differences observed among immunized as well as non-immunized study participants in considering median age, gender, age categories, IgM levels, or IgM seropositivity. Predictably, there was an important variation in IgG median values and IgG positivity noticed among the immunized and non-immunized categories as well as between populations with and without preceding infections. Our research is hence coherent with prospective requirements for booster shots to assist in controlling the rate of infections and fatality rates together throughout the pandemic conditions.
  • Correlation of Robust Immune Response against SARS-CoV-2 Vaccine among Diabetic and Non-Diabetic Participants
    Balamurali Venkatesan, L. Vajravelu, S. Ravi, Jayaprakash Thulukanam, Om Lokesh Muthamilan
    Biomedical and Pharmacology Journal, 2024
    Individuals with Type-2 diabetic mellitus (T2DM) along with several other disease-causing factors are impacted adversely by the SARS-CoV-2 pandemic. In India, BBV-152 (CovaxinTM) and ChAdOx1-nCOV (CovishieldTM) vaccines are now being used to limit the spread of SARS-CoV-2 Infection. Adaptive immunity like humoral and T-cell-mediated immunity has a vital role in eliminating SARS-CoV-2. In order to control the disease's course, the infected cells are being destroyed predominantly by cytotoxic CD8+ T cells as well as specific antibodies against SARS-CoV-2 which have the potential to neutralize the virus. This cross-sectional study was done to identify the specific antibodies for SARS-CoV-2 in serum samples from those individuals with and without T2DM by using WANTAI SARS-CoV-2 Total Ab ELISA Kit. The present study comprises 354 study participants, among them T2DM was present in 141 (39.8%) cases and 213 (60.2%) were non-diabetic patients. Hypertension was observed in 95 (26.1%) participants and 259 (73.1%) participants were normotensive. The study participants with T2DM demonstrated lower levels of SARS-CoV-2 total antibodies having an average of 5 AU/ml over those individuals without diabetes showing an average of 12 AU/ml. Among the hypertensive patients, the total antibody levels of SARS-CoV2 are were substantially lowered to showing an average of 8 AU/ml as compared to normotensive subjects showing an average of 14 AU/ml. The results of the current study suggest that regular monitoring of the total SARS-CoV-2 antibody profile may be a useful strategy for assisting people with T2DM and hypertension in determining whether they require SARS-CoV-2 precautionary doses to maintain immunity and protect against infections.
  • Correlation of Interleukin-17 and 23 Inflammatory Markers with Genetically Transmitted Spondyloarthritis Patients at a Tertiary Care Facility, South India
    T. Jayaprakash, K.V. Leela, Balamurali Venkatesan, Sujith Ravi, Om Lokesh Muthamilan
    Journal of Pure and Applied Microbiology, 2023
    Human leukocyte antigens (HLA) are genetically derived proteins in the major histocompatibility complex. They help distinguish “self” and “non-self” antigens and are essential in interacting with the immune cells inside the body. The present research work examines the prevalence of HLA-B27 among patients suspected of Spondyloarthritis (SpA), which has also been correlated with Interleukin-17/23 Inflammatory Markers and other clinical manifestations and was carried out between August 2017 to January 2021. The patient’s blood samples were collected and tested for HLA-B27 and Interleukin-17/23 inflammatory markers. Among 289 SpA patients, 60% (172) were males, and 40% (117) were females, with a ratio of 1.5:1. Ankylosing Spondylitis (65.1%) was found to be the most prevalent subgroup of SpA among the patients, closely followed by reactive arthritis (21%), psoriatic arthritis (10.7%), undifferentiated spondyloarthritis (2.1%), and inflammatory bowel disease with associated arthritis (1%). HLA-B27 was found to be positive in 54% (156) out of 289 patients. Normal IL-17 ranges were seen in 42% of HLA-B27- positive patients, while increased IL-17 was seen in 58% of the population with positive HLA-B27 cases. IL-23 was found within normal ranges in 40% of positive HLA-B27 cases, while it was found to be increased in 60% of the positive HLA-B27 positive subjects. We concluded that HLA-B27 was found to be positive among more than half of the patient population with SpA. The early detection of HLA-B27 may aid in changing lifestyle to prevent Spondyloarthritides.
  • Analysis of Robust Immune Response among Diabetic and Non-Diabetic Individuals against SARS-CoV-2 Vaccination
    Balamurali Venkatesan, Leela Kakithakara Vajravelu, Sujith Ravi, Jayaprakash Thulukanam, Om Lokesh Muthamilan
    Journal of Pure and Applied Microbiology, 2023
    The pandemic on SARS-CoV-2 infection has adversely impacted mankind all over the globe and more importantly, amidst individuals having Type-2 diabetic mellitus (T2DM) as well as among those who produce SARS-CoV-2 intricacies. Humoral and T cell-mediated immunity are adaptive immunity has a pivotal role to play in removing pathogens, comprising SARS-CoV-2. The infected cells are being eliminated by the primarily cytotoxic CD8+ T cells as well as certain antibodies in opposition to SARS-CoV-2 among humoral immunological responses possess the capacity for neutralizing this virus or by eliminating the infected cells with the support of cytotoxic in order to manage the progression of the disease. This cross-sectional study was carried out between January 2022 to December 2022. The serum samples were used to analyze SARS-CoV-2 total Ab among individuals having and not having T2DM and several metabolic risk factors like hypertension using WANTAI SARS-CoV-2 Total Ab ELISA Kit. There were 354 individuals, of which 141 (39.8%) had T2DM and 213 (60.2%) were nondiabetic patients. T2DM showed reduced antibody levels (average 5 AU/ml) than those without diabetes (average 12 AU/ml). SARS-CoV2 total antibody levels are considerably lower in hypertension patients (8 AU/ml) over those who are normotensive (14 AU/ml). The present study implies that the continuous monitoring of the total antibody profile of SARS-CoV-2 that may be a practical strategy to help individuals with T2DM and hypertension to determine their need of precautionary doses for sustaining SARS-CoV-2 vaccines by producing immunity for protection against infections.
  • Therapeutic and Diagnostic Approaches by using Nanotechnology in SARS-CoV-2 Infections
    Balamurali Venkatesan, Leela Kakithakara Vajravelu, Sujith Ravi, Jayaprakash Thulukanam, Om Lokesh Muthamilan
    Journal of Pure and Applied Microbiology, 2022
    Severe Acute Respiratory Syndrome Corona Virus-2 infection is a universal threat in recent days, hence early diagnosis and treatment play a pivotal role in controlling the spread thereby preventing them to become endemic. A newer promising approach by Nanotechnology plays an essential role in targeting the specific pathogens for therapeutic and diagnosis of Viral infection. Certain Nano platforms like Microneedle array delivered Virus S1 subunit vaccines, spike protein nanoparticles, Lumazine synthase Nanoparticles, Silver Nanoparticles, Self-Assembling Protein Nanoparticles against Viral therapy are the upcoming applications as a therapeutic approach. Nucleic acid amplification techniques and Surface-enhanced Raman Spectroscopy shows a high specificity with the immunoassay strategy. In recent days, Colloidal Gold – Nanoparticles and silicon nanoparticles have been widely used as a point of care for quick detection of IgG and IgM antibodies obtained from the virus as a diagnostic approach. Additionally, the Nanoparticles serve as a significant improvement in Personal Protective Equipment and protect against exposure to the virus. As a result of repurposing as well as for the development of the drug, apparently, Nanoparticles themselves and their concomitant therapy or their carriers will be advantageous in making a therapeutic and diagnostic approach against Severe Acute Respiratory Syndrome Corona Virus-2 infections.
  • Correlation of phenotypic and genotypic virulence markers, antimicrobial susceptibility pattern, and outcome of Pseudomonas aeruginosa sepsis infection
    Juliana Alamu, Leela Kakithakara Vajravelu, Balamurali Venkatesan, Jayaprakash Thulukanam
    Microbial Pathogenesis, 2022
  • SARS-CoV-2 Non Responders - An Analysis of Non Responsiveness to SARS-CoV-2 Vaccines among Healthcare Workers in 2021
    Balamurali Venkatesan, Leela Kakithakara Vajravelu, Sujith Ravi, Jayaprakash Thulukanam, Om Lokesh Muthamilan
    Journal of Pure and Applied Microbiology, 2022

RECENT SCHOLAR PUBLICATIONS

  • Erysipeloid
    N Vaghesan, B Venkatesan, K Govindarajan Karthikeyan
    Textbook of Bacterial Zoonoses, 211-222 , 2026
    2026
  • Rickettsial Pox
    N Vaghesan, B Venkatesan, KG Karthikeyan
    Textbook of Bacterial Zoonoses, 527-536 , 2026
    2026
  • Epidemic Typhus
    N Vaghesan, B Venkatesan, K Govindarajan Karthikeyan
    Textbook of Bacterial Zoonoses, 511-525 , 2026
    2026
  • Nanoplatform-Based Theranostics in Glioblastoma: A Promising Frontier for Precision Oncology
    KG Karthikeyan, B Venkatesan, N Vaghesan, P Selvan, S Saikumar
    Nano Trends, 100158 , 2025
    2025
    Citations: 3
  • Characterization of Candida species from Vulvovaginal Candidiasis - Emphasis on ALS3 Gene expression
    P Deeksha, LK Vajravelu, SRS Sri, B Venkatesan, D Nair
    Research Journal of Biotechnology 20 (10), 15-20 , 2025
    2025
  • Clinico-mycological analysis of ocular infections in immunocompetent vs. immunocompromised patients
    BV Natarajan V, Akhila KA, Dhanapal N, Selvan P
    Research Journal of Biotechnology 20 (6), 147-151 , 2025
    2025
  • Microbiological spectrum of infectious keratitis: Insights from a multi-speciality hospital setting
    HV Natarajan V, Balamurali Venkatesan, Akhila KA, Selvan P
    Research Journal of Biotechnology 20 (3), 49-53 , 2025
    2025
  • Rise of Carbapenem-Resistant Escherichia coli and the Concerning Existence of blaNDM-1 Gene in Gut Microbiota of Rural Populations
    A Yadhunandan, RSS Surya, LK Vajravelu, B Venkatesan, P Deeksha, ...
    J Pure Appl Microbiol , 2024
    2024
  • Association of Robust Anti-SARS-CoV-2 Trajectories among Communities with and without COVID-19 Infection
    B Venkatesan, LK Vajravelu, S Ravi, J Thulukanam, OL Muthamilan
    Journal of Pure and Applied Microbiology 18 (3), 1558-1565 , 2024
    2024
  • Nanotechnological Insights on Therapeutic Strategies for Diabetic Nephropathy
    VN Balamurali venkatesan, Pavithra selvan
    Medical Research and Its Applications 3, 145-177 , 2024
    2024
  • A Narrative Review Unveiling Novel Molecular Targets in Advancing Antidiabetic Medications: An Emerging Perspective
    AAK Balamurali Venkatesan, V Natarajan
    Journal of Clinical and Diagnostic Research 18 (5), OE05 - OE11 , 2024
    2024
    Citations: 1
  • Correlation of Robust Immune Response against SARS-CoV-2 Vaccine among Diabetic and Non-Diabetic Participants
    B Venkatesan, LK Vajravelu, S Ravi, J Thulukanam, OL Muthamilan
    Biomedical and Pharmacology Journal 17 (1), 401-407 , 2024
    2024
  • Correlation of Interleukin-17 and 23 Inflammatory Markers with Genetically Transmitted Spondyloarthritis Patients at a Tertiary Care Facility, South India
    T. Jayaprakash, K.V. Leela, Balamurali Venkatesan
    Journal of Pure and Applied Microbiology 17 (2) , 2023
    2023
    Citations: 2
  • Investigation of B cell lines and primary human B cells for in Vitro Immunological Enhancement
    JT Sujith Ravi, Leela Kakithakara Vajravelu, Balamurali Venkatesan
    European Chemical Bulletin 12 (4), 9467-9474 , 2023
    2023
  • Cancer Adoptive Immunotherapy Exploits Regressing Cancer Cells to Stimulate B Cells By In Vitro Method
    JT Sujith Ravi, Leela Kakithakara Vajravelu, Balamurali Venkatesan
    European Chemical Bulletin 12 (4), 9460-9466 , 2023
    2023
  • Analysis of Robust Immune Response among Diabetic and Non-Diabetic Individuals against SARS-CoV-2 Vaccination
    V Balamurali, R. Sujith, K. V. Leela, T. Jayaprakash
    Journal of Pure and Applied Microbiology 17 (1), 395-402 , 2023
    2023
    Citations: 3
  • Episode Of Endometrial Tuberculosis Among Infertile Patients In 2019 – 2021
    LK Vajravelu, J Thulukanam, DB Venkatesan, S Ravi, OL Muthamilan
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS 13 (5), 2005-2008 , 2022
    2022
    Citations: 1
  • Comparison Of Primary Human B Cells And B Cell Lines After Invitro Immune Stimulation
    PS Sujith Ravi, Leela Kakithakara Vajravelu, Balamurali Venkatesan ...
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS 13 (Special Issue 5), 1900-1904 , 2022
    2022
    Citations: 2
  • Therapeutic and Diagnostic Approaches by using Nanotechnology in SARS-CoV-2 Infections
    SR Balamurali Venkatesan, Leela Kakithakara Vajravelu
    Journal of Pure and Applied Microbiology 16 (4), 2324-2336 , 2022
    2022
    Citations: 4
  • Carbapenem resistant Klebsiella pneumoniae–an emerging global threat
    R Sivaramakrishnan, L Vajravelu, B Venkatesan
    J. Pharm. Negat. Results 13, 827-831 , 2022
    2022
    Citations: 1

MOST CITED SCHOLAR PUBLICATIONS

  • Correlation of phenotypic and genotypic virulence markers, antimicrobial susceptibility pattern, and outcome of Pseudomonas aeruginosa sepsis infection
    J Alamu, LK Vajravelu, B Venkatesan, J Thulukanam
    Microbial pathogenesis 170, 105716 , 2022
    2022
    Citations: 12
  • Efficacy of Green Synthesised Iron Oxide Nanoparticles against Various Uropathogens: A Cross-sectional Study
    RH Lathakumari, S Ravi, S Trisal, LK Vajravelu, D Vishnudasan, ...
    Journal of Clinical and Diagnostic Research 16 (10), DC05-DC10 , 2022
    2022
    Citations: 7
  • Therapeutic and Diagnostic Approaches by using Nanotechnology in SARS-CoV-2 Infections
    SR Balamurali Venkatesan, Leela Kakithakara Vajravelu
    Journal of Pure and Applied Microbiology 16 (4), 2324-2336 , 2022
    2022
    Citations: 4
  • SARS-CoV-2 Non Responders–an Analysis of Non Responsiveness to SARS-CoV-2 Vaccines among Healthcare Workers in 2021
    B Venkatesan, LK Vajravelu, S Ravi, J Thulukanam, OL Muthamilan
    J Pure Appl Microbiol 16 (2), 1187-1191 , 2022
    2022
    Citations: 4
  • Nanoplatform-Based Theranostics in Glioblastoma: A Promising Frontier for Precision Oncology
    KG Karthikeyan, B Venkatesan, N Vaghesan, P Selvan, S Saikumar
    Nano Trends, 100158 , 2025
    2025
    Citations: 3
  • Analysis of Robust Immune Response among Diabetic and Non-Diabetic Individuals against SARS-CoV-2 Vaccination
    V Balamurali, R. Sujith, K. V. Leela, T. Jayaprakash
    Journal of Pure and Applied Microbiology 17 (1), 395-402 , 2023
    2023
    Citations: 3
  • Overcoming strategies for non-responders in HBV vaccination
    V Balamurali, R Sujith, KV Leela, T Jayaprakash
    Journal of Advances in Microbiology 20 (8), 54-62 , 2020
    2020
    Citations: 3
  • Antibiotics in combination with antifungals to combat drug resistant Candida–a concept on drug repurposing
    H Monalis, R Sujith, KV Leela, V Balamurali
    Journal of Advances in Microbiology 20 (8), 42-48 , 2020
    2020
    Citations: 3
  • Correlation of Interleukin-17 and 23 Inflammatory Markers with Genetically Transmitted Spondyloarthritis Patients at a Tertiary Care Facility, South India
    T. Jayaprakash, K.V. Leela, Balamurali Venkatesan
    Journal of Pure and Applied Microbiology 17 (2) , 2023
    2023
    Citations: 2
  • Comparison Of Primary Human B Cells And B Cell Lines After Invitro Immune Stimulation
    PS Sujith Ravi, Leela Kakithakara Vajravelu, Balamurali Venkatesan ...
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS 13 (Special Issue 5), 1900-1904 , 2022
    2022
    Citations: 2
  • Cancer Adoptive Immunotherapy–An In Vitro Mediation Of Activated B Cells By Regressing Tumour Cells
    S Ravi, LK Vajravelu, B Venkatesan, J Thulukanam
    Journal of Pharmaceutical Negative Results, 1705-1709 , 2022
    2022
    Citations: 2
  • A Narrative Review Unveiling Novel Molecular Targets in Advancing Antidiabetic Medications: An Emerging Perspective
    AAK Balamurali Venkatesan, V Natarajan
    Journal of Clinical and Diagnostic Research 18 (5), OE05 - OE11 , 2024
    2024
    Citations: 1
  • Episode Of Endometrial Tuberculosis Among Infertile Patients In 2019 – 2021
    LK Vajravelu, J Thulukanam, DB Venkatesan, S Ravi, OL Muthamilan
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS 13 (5), 2005-2008 , 2022
    2022
    Citations: 1
  • Carbapenem resistant Klebsiella pneumoniae–an emerging global threat
    R Sivaramakrishnan, L Vajravelu, B Venkatesan
    J. Pharm. Negat. Results 13, 827-831 , 2022
    2022
    Citations: 1
  • Erysipeloid
    N Vaghesan, B Venkatesan, K Govindarajan Karthikeyan
    Textbook of Bacterial Zoonoses, 211-222 , 2026
    2026
  • Rickettsial Pox
    N Vaghesan, B Venkatesan, KG Karthikeyan
    Textbook of Bacterial Zoonoses, 527-536 , 2026
    2026
  • Epidemic Typhus
    N Vaghesan, B Venkatesan, K Govindarajan Karthikeyan
    Textbook of Bacterial Zoonoses, 511-525 , 2026
    2026
  • Characterization of Candida species from Vulvovaginal Candidiasis - Emphasis on ALS3 Gene expression
    P Deeksha, LK Vajravelu, SRS Sri, B Venkatesan, D Nair
    Research Journal of Biotechnology 20 (10), 15-20 , 2025
    2025
  • Clinico-mycological analysis of ocular infections in immunocompetent vs. immunocompromised patients
    BV Natarajan V, Akhila KA, Dhanapal N, Selvan P
    Research Journal of Biotechnology 20 (6), 147-151 , 2025
    2025
  • Microbiological spectrum of infectious keratitis: Insights from a multi-speciality hospital setting
    HV Natarajan V, Balamurali Venkatesan, Akhila KA, Selvan P
    Research Journal of Biotechnology 20 (3), 49-53 , 2025
    2025